Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 31,500 shares, a decline of 58.7% from the December 15th total of 76,200 shares. Based on an average trading volume of 787,700 shares, the days-to-cover ratio is currently 0.0 days.

Astellas Pharma Trading Up 0.6 %

Shares of ALPMY stock opened at $9.54 on Wednesday. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average of $10.14 and a 200-day moving average of $11.02. The firm has a market cap of $17.26 billion, a P/E ratio of 45.43 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. The firm had revenue of $3.11 billion for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. Sell-side analysts anticipate that Astellas Pharma will post 0.61 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.